Because 5 out of the 13 NAFLD patients with SEMA7A mutations were heterozygous for SEMA7AR148W, we also characterized Sema7aR145W (equivalent to human SEMA7AR148W) heterozygous mice in order to further investigate the functional role of SEMA7A mutations in the progression of NAFLD. Here, SEMA7A is linked to metabolic dysfunction-associated steatotic liver disease.